Table I.
Mutational status and mutation location for all 119 patients with GIST, assessed by standard methods reverse transcription-quantitative PCR and Sanger sequencing.
| Mutation genotype | n (%) |
|---|---|
| KIT/PDGFRA/BRAF-mutant GIST | |
| KIT exon 11 | 81 (68.1) |
| KIT exon 9 | 9 (7.6) |
| KIT exon 13 | 1 (0.8) |
| KIT exons 9 and 13a | 1 (0.8) |
| KIT exons 11 and 17b | 2 (1.7) |
| KIT exons 13 and 17b | 1 (0.8) |
| PDGFRA exon 12 | 1 (0.8) |
| PDGFRA exon 14 | 1 (0.8) |
| PDGFRA exon 18 | 3 (2.5) |
| BRAF | 0 |
| KIT/PDGFRA/BRAF wild-type GIST | 17 (14.3) |
| Not determined/Unknown | 1 (0.8) |
a
two primary mutations;
b
sample taken and analyzed after beginning of treatment with imatinib; GIST, gastrointestinal stromal tumors.